{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T08:17:25Z","timestamp":1775463445704,"version":"3.50.1"},"reference-count":27,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Non-Hodgkin Lymphoma patients respond differently to therapy according to inherent biological variations. Pretherapy biomarkers may improve dose-response prediction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>Hybrid single-photon emission computed tomography (SPECT)\/computed tomography (CT) three-dimensional imaging at multiple time points plus follow-up positron emission tomography (PET)\/CT or CT at 2 and 6 months post therapy were used to fit tumor response to combined biological effect and cell clearance models from which three biological effect response parameters (radiosensitivity, cold effect sensitivity, and proliferation potential) were determined per patient. A correlation of biological effect parameters and pretherapy biomarker data (ki67, p53, and phospho-histone H3) allowed a dose-based equivalent biological effect (EBE) to be calculated for each patient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Significant correlations were found between biological effect parameters and pretherapy biomarkers. Optimum correlations were found by splitting the patient data according to p53 status. Response correlation of progression free survival (PFS) and EBE were significantly improved compared with PFS and absorbed dose alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>It is possible and desirable to use pretherapy biomarkers to enhance the predictive potential of dose calculations for patient-specific treatment planning.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cbr.2017.2182","type":"journal-article","created":{"date-parts":[[2017,10,30]],"date-time":"2017-10-30T14:11:34Z","timestamp":1509372694000},"page":"309-319","source":"Crossref","is-referenced-by-count":2,"title":["Beyond Dose: Using Pretherapy Biomarkers to Improve Dose Prediction of Outcomes for Radioimmunotherapy of Non-Hodgkin Lymphoma"],"prefix":"10.1177","volume":"32","author":[{"given":"Peter L.","family":"Roberson","sequence":"first","affiliation":[{"name":"University of Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren B.","family":"Smith","sequence":"additional","affiliation":[{"name":"University of Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meredith A.","family":"Morgan","sequence":"additional","affiliation":[{"name":"University of Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew J.","family":"Schipper","sequence":"additional","affiliation":[{"name":"University of Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott J.","family":"Wilderman","sequence":"additional","affiliation":[{"name":"University of Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anca M.","family":"Avram","sequence":"additional","affiliation":[{"name":"University of Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark S.","family":"Kaminski","sequence":"additional","affiliation":[{"name":"University of Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuni K.","family":"Dewaraja","sequence":"additional","affiliation":[{"name":"University of Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.4.1259"},{"key":"e_1_3_3_3_2","first-page":"260","article-title":"Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131i-ANTI-B1 antibody: Assessment of tumor dose-response","volume":"44","author":"Sgouros G","year":"2003","unstructured":"Sgouros G, , Squeri S, , Ballangrud AM, et al. Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131i-ANTI-B1 antibody: Assessment of tumor dose-response. J Nucl Med, 2003; 44:260\u2013268.","journal-title":"J Nucl Med"},{"key":"e_1_3_3_4_2","first-page":"1155","article-title":"I-131 tositumomab radioimmunotherapy: Initial tumor dose-response results using 3-D dosimetry including radiobiological modeling","volume":"51","author":"Dewaraja YK","year":"2010","unstructured":"Dewaraja YK, , Schipper MJ, , Roberson PL, et al. I-131 tositumomab radioimmunotherapy: Initial tumor dose-response results using 3-D dosimetry including radiobiological modeling. JNM, 2010; 51:1155\u20131162.","journal-title":"JNM"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2012.1299"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.113.136044"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.109.067298"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-010-1699-3"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2012.1467"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2824-5"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2016.206"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-001071"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2303.2000.00234.x"},{"key":"e_1_3_3_14_2","first-page":"699","article-title":"Loss of the p53 tumor suppressor activity is associated with negative prognosis of mantle cell lymphoma","volume":"36","author":"Stefancikova L","year":"2010","unstructured":"Stefancikova L, , Moulis M, , Fabian P, et al. Loss of the p53 tumor suppressor activity is associated with negative prognosis of mantle cell lymphoma. Int J Oncol, 2010; 36:699\u2013706.","journal-title":"Int J Oncol"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.1711660305"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s000660050010"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.4103\/0973-1482.59901"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-010-0945-x"},{"key":"e_1_3_3_19_2","first-page":"129","article-title":"Cancer biomarkers\u2014Current perspectives","volume":"132","author":"Bhatt AN","year":"2010","unstructured":"Bhatt AN, , Mathur R, , Farooque A, et al. Cancer biomarkers\u2014Current perspectives. Indian J Med Res, 2010; 132:129\u2013149.","journal-title":"Indian J Med Res"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/110.1.24"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10384"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1088\/0031-9155\/52\/3\/017"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1109\/TNS.2006.889164"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2011.1053"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1259\/0007-1285-58-690-515"},{"key":"e_1_3_3_26_2","first-page":"70","article-title":"Malignant lymphomas stem from different B cell populations","volume":"67","author":"Kluin PM","year":"1997","unstructured":"Kluin PM, , Han J, , van Krieken JM. Malignant lymphomas stem from different B cell populations. Chem Immunol, 1997; 67:70\u201384.","journal-title":"Chem Immunol"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.990220306"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2934"}],"container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cbr.2017.2182","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cbr.2017.2182","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cbr.2017.2182","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T07:36:00Z","timestamp":1775460960000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cbr.2017.2182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.1089\/cbr.2017.2182"],"URL":"https:\/\/doi.org\/10.1089\/cbr.2017.2182","relation":{},"ISSN":["1084-9785","1557-8852"],"issn-type":[{"value":"1084-9785","type":"print"},{"value":"1557-8852","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11]]}}}